-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Rocket Pharmaceuticals, Raises Price Target to $10

Benzinga·02/27/2026 14:40:23
Listen to the news
Cantor Fitzgerald analyst Josh Schimmer maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and raises the price target from $8 to $10.